TABLE 4.
Treatment-related adverse events in patients with hepatocellular carcinoma.
| Effect | All grades | Grade ≥3 | ||
|---|---|---|---|---|
| HBV–HCC (n = 28) | NBNC–HCC (n = 26) | HBV–HCC (n = 28) | NBNC–HCC (n = 26) | |
| RCCEP | 13 (46.4) | 11 (42.3) | 0 (0.0) | 0 (0.0) |
| Proteinuria | 6 (21.4) | 6 (23.1) | 0 (0.0) | 1 (3.8) |
| Thrombocytopenia | 5 (17.8) | 4 (15.4) | 0 (0.0) | 1 (3.8) |
| Neutropenia | 3 (10.7) | 2 (7.7) | 0 (0.0) | 0 (0.0) |
| Leukopenia | 3 (10.7) | 2 (7.7) | 0 (0.0) | 0 (0.0) |
| Hypothyroidism | 3 (10.7) | 4 (15.4) | 0 (0.0) | 1 (3.8) |
| Hypertension | 4 (14.3) | 5 (19.2) | 0 (0.0) | 1 (3.8) |
| Rash | 2 (7.1) | 3 (11.5) | 1 (3.6) | 0 (0.0) |
| Nausea | 4 (14.3) | 3 (11.5) | 0 (0.0) | 0 (0.0) |
| Diarrhea | 5 (17.9) | 4 (15.4) | 1 (3.6) | 0 (0.0) |
| Fatigue | 4 (14.3) | 3 (11.5) | 0 (0.0) | 0 (0.0) |
| Myocarditis | 1 (7.1) | 0 (3.8) | 1 (3.6) | 0 (0.0) |
| Hyperbilirubinemia | 5 (17.9) | 6 (23.1) | 1 (3.6) | 0 (0.0) |
| Elevated ALT | 7 (25.0) | 4 (15.4) | 2 (7.1) | 1 (3.8) |
| Elevated AST | 6 (21.4) | 6 (23.1) | 1 (3.6) | 1 (3.8) |
Data in brackets represent the percentages of patients. HBV–HCC, hepatitis B virus-related hepatocellular carcinoma; NBNC–HCC, non-HBV; non-HCV, hepatocellular carcinoma; RCCEP, reactive cutaneous capillary endothelial proliferation; AST, aspartate aminotransferase; ALT, alanine aminotransferase.